EQUUS TOTAL RETURN, INC. (EQS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2025-12-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2025-12-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | (m) | |
| Stock-based compensation | 270.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | |
| Interest expense · reported / estimated | 683.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | (m) | (m) | $270.00K | (m) | $683.00K | (m) | (m) | (m) | Reported |
| 2025-09-30 | (m) | (m) | (m) | (m) | $501.00K | (m) | (m) | (m) | Reported |
| 2025-06-30 | (m) | (m) | $1.86M | (m) | $152.00K | (m) | (m) | (m) | Reported |
| 2025-03-31 | (m) | (m) | (m) | (m) | $135.00K | (m) | (m) | (m) | Reported |
| 2024-12-31 | (m) | (m) | $1.76M | (m) | $138.00K | (m) | (m) | (m) | Reported |
| 2024-09-30 | (m) | (m) | (m) | (m) | $140.00K | (m) | (m) | (m) | Reported |
| 2024-06-30 | (m) | (m) | $2.03M | (m) | $89.00K | (m) | (m) | (m) | Reported |
| 2024-03-31 | (m) | (m) | (m) | (m) | $56.00K | (m) | (m) | (m) | Reported |
| 2023-12-31 | (m) | (m) | $1.94M | (m) | $25.00K | (m) | (m) | (m) | Reported |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $1.56M | (m) | $4.00K | (m) | (m) | (m) | Reported |
| 2022-09-30 | (m) | (m) | (m) | (m) | $4.00K | (m) | (m) | (m) | Reported |
| 2022-06-30 | (m) | (m) | (m) | (m) | $3.00K | (m) | (m) | (m) | Reported |
| 2022-03-31 | (m) | (m) | (m) | (m) | $4.00K | (m) | (m) | (m) | Reported |
| 2021-12-31 | (m) | (m) | $0.00 | (m) | $3.00K | (m) | (m) | (m) | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $80.00K | (m) | $27.00K | (m) | (m) | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.